TheraRadar
Data updated: May 26, 2026

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE (dexbrompheniramine maleate)

Respiratory Approved 2013-02-27
1
Indication
--
Phase 3 Trials
13
Years on Market

Details

Status
Discontinued
First Approved
2013-02-27
Routes
ORAL
Dosage Forms
TABLET, EXTENDED RELEASE

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE Approval History

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2013 to 2013
Feb 2013 ORIGINAL
Update

What DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE Treats

1 FDA approvals

Originally approved for its first indication in 2013 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE FDA Label Details

Track DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.